Developing medical devices and diagnostics requires rapid problem-solving, advanced testing, and seamless collaboration across scientific and regulatory domains. For MedTech companies, internal teams may be strong—but even the best teams can’t do everything alone. A hybrid partnership model offers a solution: integrating external specialists into core workflows, without losing control or cohesion. Jordi Labs, now part of RQM+, exemplifies this approach. By offering advanced chemical and material analysis as an on-demand extension of internal R&D, quality, and regulatory teams, Jordi Labs accelerates critical milestones and reduces bottlenecks. Here’s how a hybrid partnership with Jordi Labs can transform your MedTech development pipeline.
What Is a Hybrid Partnership in MedTech?
A hybrid partnership blends the advantages of internal team leadership with the depth and agility of external expertise. Unlike standard outsourcing, this model creates close, collaborative relationships—where external partners function as embedded team members.
Core features of the hybrid model:
- Flexible resource augmentation without increasing headcount
- Direct collaboration with scientists who understand your product
- Scalable testing and analytical capacity on demand
With Jordi Labs, MedTech teams gain continuous access to world-class chemical analysis—aligned with internal goals and timelines.
The Benefits of Hybrid Collaboration With Jordi Labs
1. On-Demand Expertise When It Matters Most
Chemical and material issues don’t follow a schedule. Whether you’re facing a pre-submission deadline, an unexpected test result, or a materials selection decision, access to responsive expertise is critical.
Jordi Labs delivers:
- Rapid extractables & leachables (E&L) testing and material characterization
- Expert interpretation of analytical results
- Proactive resolution of possible regulatory concerns through real-time problem-solving
- Guidance on regulatory and biocompatibility implications
This means fewer delays, faster troubleshooting, and more confidence across design and validation phases.
2. Seamless Integration Into Internal Teams
Jordi Labs doesn’t operate at arm’s length. Instead, their scientists collaborate directly with your team—through joint planning, data interpretation, and regulatory alignment.
Collaboration includes:
- Shared project plans and timelines
- Frequent communication and co-development of testing protocols
- Co-authored content for regulatory submissions (e.g., ISO 10993, FDA 510(k), EU MDR)
This level of integration ensures that results aren’t just accurate—they’re actionable.
3. Accelerated Regulatory and Preclinical Readiness
Jordi Labs is recognized for scientific excellence and regulator-trusted methods. Their research is often cited directly in regulatory decisions, providing credibility that accelerates the approval process.
Their expertise supports:
- ISO 10993-18 chemical characterization
- ISO 10993-17 toxicological risk assesment
- FDA, EMA, and MDR/IVDR regulatory filings
- Preclinical safety assessments for novel materials and formulations
- Investigative resolution of complex analytical or material challenges
By combining speed with scientific rigor, they help sponsors meet critical deadlines without sacrificing quality.
4. Expanded Analytical Capacity—Without Fixed Overhead
Building in-house chemical analysis labs or hiring full-time experts can be costly and inflexible. The hybrid model solves this by offering access to specialized capabilities only when needed.
With Jordi Labs, you gain:
- Over 60 analytical techniques and advanced instrumentation
- A team of Ph.D.-level chemists and materials scientists
- State-of-the-art instrumentation exceeding regulator expectations
- The ability to flex capacity based on project volume and urgency
This is ideal for startups managing constrained budgets and enterprises juggling multiple development timelines.
Real-World Applications of the Hybrid Model
Material selection:
Jordi supports early-stage teams by identifying safe, durable polymers and coatings, preventing downstream issues in performance or biocompatibility.
Regulatory submissions:
Jordi supports the full ISO 10993 submission process, with E&L data, biological testing, toxicological risk assesment and expert analysis that are trusted by regulators for their clarity, scientific rigor, and completeness.
Failure analysis:
When devices degrade, discolor, or malfunction, Jordi identifies the root chemical or material cause, enabling fast design corrections or CAPAs.
The Integrated Strength of Jordi Labs and RQM+
As a member of the RQM+ family, Jordi Labs operates within a broader ecosystem of MedTech regulatory, clinical, and quality services. This provides clients with:
- Multidisciplinary expertise across product development and compliance
- Unified support from preclinical testing to post-market surveillance
- Faster problem-solving at the intersection of science and regulation
Together, RQM+ and Jordi Labs provide end-to-end support that’s agile, precise, and deeply informed by real-world challenges.
Looking for MedTech Support?
The hybrid partnership model with Jordi Labs allows MedTech innovators to extend their capabilities without adding complexity. Whether navigating regulatory hurdles, refining material choices, or resolving unexpected test results, Jordi provides the expertise, speed, and flexibility that modern development demands. Backed by RQM+, this partnership empowers teams to move faster, solve smarter, and deliver safer devices to market. In today’s MedTech landscape, hybrid collaboration isn’t just efficient—it’s essential. Contact us to talk MedTech support today.
